logo-loader
viewZelda Therapeutics Ltd

Zelda Therapeutics secures patent to detect breast cancer

Building an intellectual property portfolio is part of Zelda's vertically integrated strategy.

folder titled patents
The patent provides protection until 2038

Zelda Therapeutics Ltd (ASX:ZLD) has been granted a new patent in Australia covering a novel method to predict patient disease-free survival.

The patent details a method for detecting levels of expression of a novel receptor complex containing HER2 and CB2 (types of protein).

HER2 is a well-recognised marker of aggressive breast cancer while CB2 is a key receptor in the endocannabinoid system.

Together they form a novel receptor complex that represents a prognostic marker for HER2 positive breast cancer.

READ: Zelda Therapeutics leveraged to study results that progress cannabis-based cancer therapies

Zelda’s managing director Dr Richard Hopkins said: “We’re delighted with the allowance of this patent, which supports Zelda’s strategy of building a world-class intellectual property portfolio and the development of cannabis-based products.

“Further news is expected as this patent family progresses through the international examination phase.

“I’d also like to acknowledge the work of Professor Cristina Sanchez and her team who generated the data that supported this patent.

“This work was recently published in the prestigious peer-reviewed Proceedings of the National Academy of Sciences.

“This outcome highlights the benefit of Zelda’s approach of partnering with world-leading cannabis researchers.

“Importantly, Professor Sanchez’s discovery of a novel prognostic biomarker, will complement our ongoing efforts develop to cannabis-based medicines to treat breast cancer.”

A vertically integrated medical cannabis strategy

The company’s focus remains on the development of novel cannabinoid-based therapies for a range of diseases.

Zelda is undertaking a human clinical trial program focused on insomnia, autism and opioid reduction with activities in Australia and the US.

Pre-clinical research activities include programs examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Quick facts: Zelda Therapeutics Ltd

Price: 0.069 AUD

ASX:ZLD
Market: ASX
Market Cap: $52.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelda Therapeutics Ltd named herein, including the promotion by the Company of Zelda Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Ilera Healthcare deal is 'one piece of the puzzle' for Zelda Therapeutics in...

Zelda Therapeutics Ltd (ASX:ZLD, OTCBB:ZLDAF) managing director Dr Richard Hopkins speaks to Proactive Investors about the medical cannabis researcher's binding heads of agreement (HoA) with US-based medicinal cannabis company Ilera Healthcare LLC. The deal complements a number of...

on 03/12/2019

2 min read